BioStem Technologies Other 8-K Filing
BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, allowing the company to sell shares of common stock at its discretion over a 36-month period. The facility provides opportunistic access to capital for working capital and general corporate purposes, though no shares were sold at the time of the filing. Sales are subject to a registration statement being declared effective and a minimum threshold price of $1.00 per share.
- Counterparty
- Roth Principal Investments, LLC
- Term
- 36 months